Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations. 

TLX101 follows Ipax-1 with an apparent success in an academic trial.

The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.